National Health (Pharmaceutical Benefits) Regulations (Amendment) (Cth)

Statutory Rules

1976 No. 150

REGULATIONS UNDER THE NATIONAL HEALTH ACT 1953.*

WHEREAS it is provided by sub-section 101 (4) of the National. Health Act 1953 that a drug or medicinal preparation that was not a pharmaceutical benefit under that Act immediately before the commencement of that sub-section shall not be prescribed as a pharmaceutical benefit in accordance with section 85 of that Act unless the Pharmaceutical Benefits Advisory Committee has recommended to the Minister that it be so prescribed:

AND WHEREAS that Committee has recommended to the Minister that the following drugs and medicinal preparations be prescribed as pharmaceutical benefits under section 85 of the National Health Act 1953, namely the drugs and medicinal preparations specified in the Third Schedule to the National Health (Pharmaceutical Benefits) Regulations, as amended by the following Regulations, that had not previously been prescribed as pharmaceutical benefits:

NOW THEREFORE I, THE GOVERNOR-GENERAL of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Regulations under the National Health Act 1953.

Dated this twenty-second day of July, 1976.

John R. Kerr

Governor-General.

By His Excellency’s Command,

Minister of State for Health.

_________

Amendments of the National Health (Pharmaceutical Benefits) Regulations 

Commencement.

1.These Regulations shall come into operation on 1 August 1976.

First Schedule.

2.The First Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in Schedule 1.

Second Schedule.

3.The Second Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in Schedule 2.

Third Schedule.

4.The Third Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in Schedule 3.

Fifth Schedule.

5.The Fifth Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in Schedule 4.

_________________________________________________________________________________

* Notified in the Australian Government Gazette on 26 July, 1976.

  Statutory Rules 1960, No. 17, as amended to date. For previous amendments of the National Health (Pharmaceutical Benefits) Regulations see footnote   to Statutory Rules 1976, No. 84 and see also Statutory Rules 1976, No. 84.

13826/76—Recommended retail price 15c 10/6.7.1976

SCHEDULE 1 Regulation 2

Amendments of the First Schedule to the National Health (Pharmaceutical Benefits) Regulations

1. Omit item 320.

2. After item 535 insert the following item:—

“ 535a Senna Tablets ”.

3. After item 575 insert the following item:—

“ 575a Sulphadimethoxine Tablets ”.

________

SCHEDULE 2 Regulation 3

Amendments of the Second Schedule to the National Health (Pharmaceutical Benefits) Regulations

1. After item 35 insert the following item:—

“ 35a Carbidopa Levodopa, B.P., with Carbidopa ”.

2. After item 114 insert the following item:—

“114a Levodopa, B.P. Carbidopa with Levodopa, B.P.”.

_________

SCHEDULE 3 Regulation 4

Amendments of the Third Schedule to the National Health (Pharmaceutical Benefits) Regulations

1. After item 57 insert the following item:—

“ 57a Carbidopa ”.

2. After item 262 insert the following item:—

“ 262a Prochlorperazine Edisylate ”.

3. After item 330 insert the following item:—

“ 330a Tobramycin Sulphate ”.

_________

SCHEDULE 4 Regulation 5

Amendments of the Fifth Schedule to the National Health (Pharmaceutical Benefits) Regulations

1. Omit item 19 substitute the following item:—
“ 19	(1) Calciferol, B.P...................	With the written authority of the Director-General—
(2) Calciferol Tablets, Strong, B.P.	Hypocalcaemia
	Hypoparathyroidism
Osteomalacia following gastrectomy, severe steatorrhoea or renal failure
Vitamin D-resistant rickets ”.
2. Omit item 39 substitute the following item:—
“ 39	(1) Codeine Phosphate with Aspirin and Paracetamol Soluble Tablets	Any disease or condition in a pensioner ”.
(2) Codeine Phosphate with Aspirin Soluble Tablets
(3) Codeine Phosphate with Aspirin and Paracetamol Tablets (8mg-250mg-250mg tablets)
3. Omit item 72.
4. After item 85 insert the following item:—
“ 85a	Levodopa, B.P., with Carbidopa	With the written authority of the Director-General, treatment of Parkinson’s Disease ”.
5. Omit item 145.

Schedule 4—continued

6. Omit item 157 substitute the following item:—
“ 157	Tetracosactrin Acetate, B.P.	With the written authority of the Director-General—
Hypsarrhythmia
Multiple sclerosis, acute exacerbation
Status asthmaticus
Treatment of children who need long-term corticosteroid therapy but who are in danger of growth suppression as a result
Treatment of patients who are being withdrawn from long-term corticosteroid therapy
Ulcerative colitis, proven, not responding to parenteral corticosteroids”.
7. Omit item 158 substitute the following item:—
“ 158	Tetracosactrin Zinc Injection, B.P.	With the written authority of the Director-General—
Hypsarrhythmia
Multiple sclerosis, acute exacerbation
Status asthmaticus
Treatment of children who need long-term corticosteroid therapy but who are in danger of growth suppression as a result
Treatment of patients who are being withdrawn from long-term corticosteroid therapy
Ulcerative colitis, proven, not responding to parenteral corticosteroids ”.
8. After item 162 insert the following item:—
“162a	Tobramycin Sulphate.............	With the written authority of the Director-General—
Infections where positive bacteriological evidence confirms that tobramycin sulphate is the most appropriate antibiotic
Septicaemia, suspected or proven ”.

                  

Printed by Authority by the Government Printer of Australia